- Home
- TOVX vs VRAX Comparison
TOVX vs VRAX Comparison
Compare TOVX & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- VRAX
- Stock Information
- Founded
- TOVX 2001
- VRAX 2013
- Country
- TOVX United States
- VRAX United Kingdom
- Employees
- TOVX N/A
- VRAX N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TOVX Health Care
- VRAX Health Care
- Exchange
- TOVX Nasdaq
- VRAX Nasdaq
- Market Cap
- TOVX 4.5M
- VRAX 4.4M
- IPO Year
- TOVX 2006
- VRAX 2022
- Fundamental
- Price
- TOVX $0.43
- VRAX $0.85
- Analyst Decision
- TOVX Hold
- VRAX Strong Buy
- Analyst Count
- TOVX 1
- VRAX 1
- Target Price
- TOVX N/A
- VRAX $3.00
- AVG Volume (30 Days)
- TOVX 371.0K
- VRAX 196.8K
- Earning Date
- TOVX 08-12-2025
- VRAX 02-05-2025
- Dividend Yield
- TOVX N/A
- VRAX N/A
- EPS Growth
- TOVX N/A
- VRAX N/A
- EPS
- TOVX N/A
- VRAX N/A
- Revenue
- TOVX N/A
- VRAX $6,331.00
- Revenue This Year
- TOVX N/A
- VRAX $217,274.83
- Revenue Next Year
- TOVX N/A
- VRAX N/A
- P/E Ratio
- TOVX N/A
- VRAX N/A
- Revenue Growth
- TOVX N/A
- VRAX N/A
- 52 Week Low
- TOVX $0.40
- VRAX $0.74
- 52 Week High
- TOVX $7.15
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- TOVX 39.54
- VRAX 43.06
- Support Level
- TOVX $0.45
- VRAX $0.78
- Resistance Level
- TOVX $0.49
- VRAX $1.00
- Average True Range (ATR)
- TOVX 0.04
- VRAX 0.11
- MACD
- TOVX -0.00
- VRAX -0.01
- Stochastic Oscillator
- TOVX 17.79
- VRAX 17.88
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).